Abstract Chemotherapy-based treatment of patients with primary central nervous system lymphoma can lead to durable remissions and potentially cure in a fraction of patients. Accurate assessment of residual disease is necessary to determine the duration and success of treatment that cannot be achieved by contrast-enhanced imaging due to limited sensitivity and specificity. A tumor-derived bloodbased biomarker, if detectable and quantifiable, could serve as a more specific and reliable marker for these patients. The goal of this study was to assess whether lymphoma-specific IgH rearrangements can be detected in plasma of patients with PCNSL. PCNSL tissue was analyzed by capturing and sequencing the IgH genomic regions (IgCap) using next generation sequencing with the Illumina platform. Plasma of patients with detected IgH rearrangement was then analyzed for presence of the respective rearrangement using polymerase chain reaction. Tumor tissue and matched plasma of five treatment-naïve patients with biopsy-proven PCNSL (mean age of 65.6 years; range 62-68 years) were analyzed. All patients had measurable contrast-enhancing disease on MRI at time of plasma collection. IgH rearrangements were identified in 4 of 5 analyzed PCNSL tissue samples. The respective rearrangement could be detected in the plasma of 1 patient (25 %) but not in the others. IgH rearrangements can be detected in tumor tissue of patients with PCNSL using IgCap, however, they are absent or only present in minimal quantities in plasma, even in treatment-natïve patients with bulky disease. Alternative strategies to develop circulating biomarkers for PCNSL patients need to be explored.
Introduction
Primary central nervous system lymphomas (PCNSL) account for about 4 % of tumors of the central nervous system. The incidence of PCNSL, however has been rising in the immunocompetent population over the last few decades, particularly in the elderly population [1, 2] .
High-dose methotrexate-based therapies are the standard of care for newly diagnosed PCNSL. Several different regimens achieve response rates of greater than 50 % and durable remissions in many patients [3] . PCNSL is now considered a potentially curable disease; however, most patients still recur after initial therapy and many eventually die of their disease.
In order to choose the appropriate duration of treatment, it is important to determine when patients have achieved a complete response (CR), which is the prerequisite for a potential cure.
Response assessment in PCNSL has commonly been based on the same response criteria used for other primary brain tumors [4, 5] , and patients are considered to have achieved a CR when all contrast-enhancing lesions have disappeared on MRI. However, PCNSL is known to diffusely involve non-contrast enhancing areas, CSF and the eyes, so contrast enhancement alone is not a reliable marker of a CR in these cancers. In addition, complete resolution of all contrast enhancing areas is not always achieved and residual contrast enhancement does not necessarily mean that there is residual disease [6] . As a result, investigators have started to focus on circulating tumor markers to assess disease status in patients with PCNSL [7] . To be clinically useful, such a marker needs to be exquisitely specific. A particularly attractive circulating biomarker is circulating tumor DNA (ctDNA), as such somatic alterations are unique to tumor cells.
The concept of mutated ctDNA as a specific and potentially sensitive circulating tumor marker has been demonstrated in several solid tumors [8] [9] [10] . Fusion genes are other genetic alterations that can function as circulating tumor markers in malignancies. Chronic myelogenous leukemia is an example of a disease in which fusion genes are routinely quantified as measure of disease burden and used for assessment of residual disease. Additionally, a recent study showed that IgH gene rearrangements could be detected in plasma of patients with non-Hodgkin's lymphoma, suggesting this as a potentially useful and highly specific blood-based tumor marker for lymphomas [11] . Based on these data, we set out to determine whether a similar IgH-based approach would be feasible in patients with PCNSL, as described below.
Methods

Sample collection
Adult patients with newly diagnosed, previously untreated, biopsy-proven PCNSL with measurable areas of contrast enhancement were asked to participate in this study. Pretreatment MRI scans were reviewed. Histologic and immunohistochemical slides of the cases included in the study were reviewed by a neuropathologist (FJR). Informed consent was obtained using a protocol that was approved by the Institutional Review Board at Johns Hopkins University. Formalin-fixed paraffin-embedded (FFPE) tissue samples were collected and used for analysis. Plasma was collected in EDTA-containing tubes, centrifuged twice immediately after collection and stored at -80°C. Plasma collection and processing was done the same way as in other circulating tumor DNA studies performed by our laboratory [8] . Plasma samples were only thawed once for DNA extraction and immediately processed to optimize sample quality.
DNA purification DNA was extracted from 10,000 ll of plasma with a QIAamp circulating nucleic acid kit following the manufacturer's instructions (QIAGEN; Valencia, CA, USA). DNA was extracted from tumor tissues using a Qiagen AllPrep kit following the manufacturer's protocol. The amount of amplifiable DNA was quantified by a real time PCR based assay that amplifies human repeated sequences [12] . 
IgCap capture
The targeted capture region included V-gene exons plus the first 36 bp of the downstream introns, six J-gene exons plus the first 36 bp of the upstream introns, and all the D-gene exons. Capture of the regions of interest was performed as described before [11, 13] . Captured DNA libraries were sequenced with the Illumina GAIIx Genome Analyzer, yielding 150 (2 9 75) base pairs from the final library fragments. Sequencing reads were analyzed and aligned to human genome hg18 with the Eland algorithm in CASAVA 1.6 software (Illumina). The sequence information was processed in silico to identify rearranged sequences as previously described [11] .
Confirmation of IgH rearrangements in tumor and plasma samples
The full V-D-J or D-J joint region sequence and 40 bp from either side of the joint were used for primer design. 
Results
Five patients with newly diagnosed, previously untreated PCNSL were studied. The patient demographics and representative MRI images are shown in Table 1 and Fig. 1 . All patients had bulky, contrast enhancing, intraparenchymal brain lesions indicating disruption of the blood-brain barrier (BBB; Fig. 1 ). DNA isolated from lymphoma tissue was used to construct libraries suited for massively parallel sequencing according to the IgCap protocol (see methods). Between 13,248,664 and 28,400,917 tags were generated per patient ( Table 2 ). The sequence information obtained was then processed in silico to identify rearranged sequences at the IgH locus. IgH rearrangements were detected in the tumor tissue of four of the five patients and each rearrangement was validated by PCR with primers flanking the rearranged region (Table 3; Supplement Table 1) .
Next, we analyzed DNA from plasma of the four patients with an identifiable rearranged IgH gene in their lymphomas. Even after extensive cycles of PCR (50), easily adequate to detect single copies of rearranged sequences [14] rearrangements could only be detected in one of the four plasma specimens analyzed (Fig. 2) . The one rearrangement that was found in plasma (Patient 1) was confirmed by direct sequencing of the PCR product; the DNA sequence was identical with the one that was detected in the corresponding lymphoma tissue.
The detectability of IgH rearrangements in plasma did not correlate with presence or absence of contrast enhancement on MRI, as all 5 patients had visible contrast enhancement at time of plasma collection.
Discussion
This study shows that IgH rearrangements can be detected in tumor tissue of patients with PCNSL and that these rearrangements can occasionally be detected in the blood. However, it appears that the detectability of circulating rearrangements is limited, even in patients with bulky, contrast-enhancing disease prior to chemotherapy. The reason for the limited detectability of IgH rearrangements in plasma of these patients is unclear. The BBB in contrast enhancing regions of lymphoma is altered (as evidenced by presence of contrast enhancement on MRI), and one would assume that DNA can be shed into the bloodstream through gaps in the disrupted BBB, in particular in PCNSL that
have not yet been treated with chemotherapy. Similar findings have been described previously by Jahnke et al. [15, 16] who analyzed 24 consecutive patients with PCNSL for presence of IgH rearrangements in blood and bone marrow using a three framework region (FR) assay. IgH rearrangements were detected in 4 of 24 patients with matched tumor and blood rearrangements were found in two patients, a similar frequency of detection to our observation [15] . Based on these combined findings, it appears that only limited quantities of tumor DNA find their way into the blood stream in patients with PCNSL and that circulating lymphoma DNA of rearranged IgH does not appear to be a useful marker of disease burden due to its low frequency of detection.
The question remains if this biomarker may be of higher yield when analyzing other compartments such as the patients' CSF. ctDNA may be present at higher concentrations in CSF; however, this assay would be more difficult to use clinically as it would require repeat lumbar punctures.
